Byeon Gihwan, Kang Dong Woo, Kim Yeshin, Kim Geon Ha, Kim Ko Woon, Kim Hee-Jin, Na Seunghee, Park Kee Hyung, Park Young Ho, Suh Jeewon, Shin Joon Hyun, Shim YongSoo, Yang YoungSoon, Um Yoo Hyun, Oh Seong-Il, Wang Sheng-Min, Yoon Bora, Lee Sun Min, Lee Juyoun, San Lee Jin, Rhee Hak Young, Lim Jae-Sung, Jung Young Hee, Chin Juhee, Jang Hyemin, Hong Yun Jeong, Choi Miyoung, Jang Jae-Won
Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea.
Dement Neurocogn Disord. 2025 Jan;24(1):24-43. doi: 10.12779/dnd.2025.24.1.24. Epub 2025 Jan 20.
Dementia often accompanies behavioral and psychological symptoms of dementia (BPSD), including agitation, aggression, depression, and psychosis, which impact patients' quality of life and caregiver burden. Effective management of BPSD is essential to support patient and caregiver well-being. This study presents evidence-based clinical practice guidelines for pharmacological treatments of BPSD in dementia, focusing on antipsychotics, antidepressants, cognitive enhancers, and other medications.
This guideline was developed by the Korean Dementia Association's Quality Management Committee. Key questions were framed using the Population, Intervention, Comparison, Outcome methodology, followed by systematic literature searches. Randomized controlled trials were assessed for quality, and recommendations were graded based on evidence levels, employing the Grading of Recommendations, Assessment, Development and Evaluation system to establish strength and applicability.
Recommendations vary by medication type and symptom severity. Antipsychotics, such as risperidone, are conditionally recommended for managing aggression and psychosis in dementia, while antidepressants, specifically citalopram, are advised for agitation in Alzheimer's disease. Cognitive enhancers, including cholinesterase inhibitors and memantine, showed moderate efficacy for general BPSD improvement and rapid eye movement sleep behavior disorder in Lewy body dementia. Specific drugs, like pimavanserin, demonstrated efficacy in addressing psychosis in Alzheimer's patients.
These guidelines provide a structured approach to pharmacological management of BPSD in dementia, addressing efficacy and safety profiles across drug categories. The recommendations emphasize personalized treatment plans to optimize therapeutic outcomes while minimizing risks, with a conditional approach suggested in cases with limited evidence.
痴呆症常伴有痴呆的行为和心理症状(BPSD),包括激越、攻击行为、抑郁和精神病,这些症状会影响患者的生活质量和照顾者的负担。有效管理BPSD对于支持患者和照顾者的幸福感至关重要。本研究提出了基于证据的痴呆症BPSD药物治疗临床实践指南,重点关注抗精神病药物、抗抑郁药物、认知增强剂和其他药物。
本指南由韩国痴呆症协会质量管理委员会制定。关键问题采用人群、干预措施、对照、结局方法进行构建,随后进行系统的文献检索。对随机对照试验进行质量评估,并根据证据水平进行推荐分级,采用推荐分级、评估、制定和评价系统来确定强度和适用性。
推荐因药物类型和症状严重程度而异。抗精神病药物,如利培酮,有条件地推荐用于管理痴呆症中的攻击行为和精神病,而抗抑郁药物,特别是西酞普兰,建议用于治疗阿尔茨海默病中的激越。认知增强剂,包括胆碱酯酶抑制剂和美金刚,对改善一般BPSD和路易体痴呆中的快速眼动睡眠行为障碍显示出中等疗效。特定药物,如匹莫范色林,在治疗阿尔茨海默病患者的精神病方面显示出疗效。
这些指南为痴呆症BPSD的药物管理提供了一种结构化方法,涉及各类药物的疗效和安全性概况。推荐强调个性化治疗方案,以优化治疗效果,同时将风险降至最低,在证据有限的情况下建议采用有条件的方法。